Adenocarcinomas News and Research

RSS

Bile DNA sequencing helps identify hidden pancreatobiliary tumors

Distinguishing malignant from benign biliary strictures remains a major clinical challenge. Endoscopic retrograde cholangiopancreatography (ERCP)-guided cytology and biopsy may be inconclusive, particularly in early-stage disease or when tissue is scarce.

29 Sep 2026

Protein-based MRI agent detects tiny lung cancer metastases

A multi-institutional research team led by Georgia State University Regents' Professor Emerita of Biochemistry and Biophysical Chemistry Jenny J. Yang has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches.

9 Sep 2026

Study identifies KRAS G12C as a precision-medicine target in genitourinary cancers

A new research paper was published in Volume 17 of Oncotarget on August 19, 2026, titled "Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine."

28 Aug 2026

Japanese study links inherited genetic variants to multiple lung cancers

Lung cancer remains the leading cause of cancer-related deaths worldwide and is generally thought to arise from mutations acquired over a lifetime through environmental exposures.

30 Jun 2026

New genetic driver found for rare small intestinal cancers

A signaling system known as the Wnt pathway plays a central role in how cells in the intestine grow, divide, and renew themselves.

12 Jun 2026

Degrading mutant KRAS protein induces greater lung cancer regression

KRAS is one of the oncogenes most frequently altered in cancer, mutated in approximately one-third of lung adenocarcinomas.

27 May 2026

Targeted RAS inhibitor shows promise against pancreatic cancer mutations

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.

7 May 2026

Clusterin inhibition offers new hope for treating cervical gastric-type adenocarcinoma

Gastric-type adenocarcinoma (GAS) is one of the most aggressive non-human papillomavirus (HPV)-associated cervical adenocarcinomas and remains especially difficult to diagnose and treat.

8 Apr 2026

Tumor microenvironment drives resistance to ferroptosis in pancreatic cancer

Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be harnessed for cancer therapy.

2 Apr 2026

Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare.

13 Mar 2026

Genomic landscape and clinicopathologic significance of POLE mutant colorectal carcinoma

DNA polymerase epsilon catalytic subunit A (POLE) gene plays a crucial role in DNA repair and chromosomal replication.

27 Feb 2026

Rising lung cancer in never smokers demands urgent research focus

Lung cancer patients who have never smoked make up a significant and growing share of global lung cancer cases, yet remain an understudied group, according to a new review written by UCL (University College London) researchers.

12 Feb 2026

Novel drug combination overcomes resistance in aggressive KRAS-mutated lung cancer

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and difficult-to-treat form of lung cancer.

13 Jan 2026

Rare case of pancreatic Hodgkin lymphoma is often misdiagnosed as pancreatic adenocarcinoma

A new case report was published in Volume 12 of Oncoscience on October 6, 2025, titled "A peculiar case of primary lymphoma of pancreas: A rare presentation of Hodgkin lymphoma."

22 Oct 2025

Research shows different EML4-ALK variants drive lung cancer aggressiveness

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK.

23 Sep 2025

TTF1 identified as key biomarker for advanced KRAS G12C-mutated non-small cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), following treatment with the KRAS targeted therapy sotorasib.

30 May 2025

Researchers discover race-associated molecular differences in pancreatic tumors

Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic cancer respond to immunotherapies.

12 Mar 2025

MICAL2 enzyme found to promote tumor growth in pancreatic cancer

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective treatment options for the disease.

2 Jan 2025

Global study reveals shifting trends in ovarian cancer incidence by subtype and region

Study analyzed global patterns and trends in ovarian cancer incidence from 1988 to 2017, highlighting variations by histological subtypes and regions. It revealed significant geographic disparities, with higher rates in regions with very high HDIs and emphasized the need for targeted prevention and surveillance strategies.

15 Dec 2024

DTI detects precancerous lesions in the pancreas

Precursor lesions of pancreatic cancer are very difficult to characterize with magnetic resonance imaging (MRI). But now, in a new study, researchers led by Noam Shemesh and Carlos Bilreiro – respectively head of the Preclinical MRI lab at Champalimaud Research and a doctor at the Champalimaud Clinical Centre's Radiology Department – have shown, for the first time, that a particular form of MRI, called Diffusion Tensor Imaging (DTI), is capable of robustly detecting pre-malignant lesions in the pancreas.

13 Dec 2024